Claims for Patent: 11,285,183

Summary for Patent: 11,285,183

Title:	Lactobacillus gasseri
Abstract:	A strain of KBL697 and the use thereof are described. The strain of KBL697 (Accession No. KCTC 13520BP) attenuates allergic reactions of cells, significantly improves symptoms of atopic dermatitis, and exhibits anti-inflammatory and anti-fungal effects and a therapeutic effect for intestinal diseases such as irritable bowel syndrome and colitis. Thus, the single strain alone can achieve all the purposes of alleviating allergic diseases and inflammatory diseases and improving intestinal health, thereby finding advantageous applications as a probiotic substance. In addition, the strain, based on the anti-fungal activity thereof, can be advantageously utilized in a skin external preparation against various skin diseases caused by fungi, and in a cosmetic composition and a functional patch for alleviating sensitive skin.
Inventor(s):	Ko Woo Ri, Lee June Chul, Park Hyo In, Nam Tae Wook, Ko Gwang Pyo, Kim Woon Ki, Han Dae Hee, Kim In Su, Lee Jin Woo, Kim Hye Jin
Assignee:	KoBioLabs, Inc.
Application Number:	US17102301
Patent Claims:

Details for Patent 11,285,183

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	December 22, 1994		2040-11-23
Aytu Bioscience, Inc.	PROSTASCINT	capromab pendetide	Injection	103608	October 28, 1996		2040-11-23
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	December 10, 1997		2040-11-23
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	May 12, 1998		2040-11-23
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	January 02, 2003		2040-11-23
Boehringer Ingelheim Pharma Gmbh & Co. Kg	VERLUMA	nofetumomab	Injection	103769	October 13, 1998		2040-11-23
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	June 19, 1998		2040-11-23